Antibe Therapeutics Stock Price, News & Analysis (CVE:ATE)

C$0.20 0.00 (0.00 %)
(As of 01/23/2018 04:00 PM ET)
Previous CloseC$0.20
Today's RangeC$0.19 - C$0.21
52-Week RangeC$0.08 - C$0.29
Volume307,715 shs
Average Volume631,934 shs
Market CapitalizationC$31.73 million
P/E Ratio-3.33
Dividend YieldN/A
Beta0.23

About Antibe Therapeutics (CVE:ATE)

Antibe Therapeutics Inc., together with its subsidiaries, originates, develops, and out-licenses patent protected pharmaceuticals primarily in Canada, Europe, and the United States. The company’s lead compound is the ATB-346, a hydrogen sulfide-releasing derivative of naproxen that is in Phase II clinical study for the treatment of osteoarthritis, as well as to treat rheumatoid arthritis, ankylosing spondylitis, and general pain reduction. Its products also comprise ATB-352, which is in preclinical stage for the treatment of gout, dental pain, post-surgical pain, etc.; and ATB-340 that is in preclinical development stage for the treatment of cardiovascular disease and cancer chemoprevention. In addition, it offers various tissue regenerating products, such as bone grafting and dental membrane solutions for the dental and orthopedic markets; and surgical instruments for dental surgery, plastic surgery, general surgery and specialties, and veterinary applications. Antibe Therapeutics Inc. was incorporated in 2009 and is headquartered in Toronto, Canada.

Receive ATE News and Ratings via Email

Sign-up to receive the latest news and ratings for ATE and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorHealthcare
SymbolCVE:ATE
CUSIPN/A
Phone+1-905-5705103

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E Ratio-3.33333333333333
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

Trailing EPSC($0.06)
Net IncomeN/A
Net Margins-76.30%
Return on Equity-152.57%
Return on Assets-58.65%

Miscellaneous

EmployeesN/A
Outstanding Shares162,967,000

Antibe Therapeutics (CVE:ATE) Frequently Asked Questions

What is Antibe Therapeutics' stock symbol?

Antibe Therapeutics trades on the Canadian Venture Exchange (CVE) under the ticker symbol "ATE."

How were Antibe Therapeutics' earnings last quarter?

Antibe Therapeutics Inc (CVE:ATE) announced its quarterly earnings results on Tuesday, November, 28th. The company reported ($0.01) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.01). Antibe Therapeutics had a negative net margin of 76.30% and a negative return on equity of 152.57%. View Antibe Therapeutics' Earnings History.

When will Antibe Therapeutics make its next earnings announcement?

Antibe Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, March, 7th 2018. View Earnings Estimates for Antibe Therapeutics.

Who are some of Antibe Therapeutics' key competitors?

Who are Antibe Therapeutics' key executives?

Antibe Therapeutics' management team includes the folowing people:

  • Walter M. Macnee, Independent Chairman of the Board
  • Daniel Legault J.D., President, Chief Executive Officer, Secretary, Director (Age 56)
  • John L. Wallace Ph.D., Founder, Chief Scientific Officer, Director (Age 57)
  • Alain S Wilson, Chief Financial Officer
  • Jeremy Grushcow, Executive Vice President - Strategic Development
  • David Vaughan, Chief Development Officer (Age 63)
  • Samira Sakhia CPA, Director
  • Yung Wu, Director
  • Roderick J. Flower Ph.D., Independent Director (Age 69)
  • Jonathan Ross Goodman, Independent Director (Age 48)

How do I buy Antibe Therapeutics stock?

Shares of Antibe Therapeutics and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.

What is Antibe Therapeutics' stock price today?

One share of Antibe Therapeutics stock can currently be purchased for approximately C$0.20.

How big of a company is Antibe Therapeutics?

Antibe Therapeutics has a market capitalization of C$31.73 million.

How can I contact Antibe Therapeutics?

Antibe Therapeutics' mailing address is 15 Prince Arthur Ave, TORONTO, ON M5R 1B2, Canada. The company can be reached via phone at +1-905-5705103.


MarketBeat Community Rating for Antibe Therapeutics (ATE)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  39 (Vote Outperform)
Underperform Votes:  30 (Vote Underperform)
Total Votes:  69
MarketBeat's community ratings are surveys of what our community members think about Antibe Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Antibe Therapeutics (CVE:ATE) Analyst Ratings History


No equities research coverage for this company has been tracked by MarketBeat

Earnings

Antibe Therapeutics (CVE:ATE) Earnings History and Estimates Chart

Earnings by Quarter for Antibe Therapeutics (CVE:ATE)

Antibe Therapeutics (CVE ATE) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/7/2018        
11/28/2017Q2 2018C($0.01)C($0.01)ViewN/AView Earnings Details
8/29/2017Q1 2018C($0.02)ViewN/AView Earnings Details
7/28/2017Q4 2017C($0.02)ViewN/AView Earnings Details
3/1/2017Q3 2017C($0.02)ViewN/AView Earnings Details
11/29/2016Q2 2017C($0.01)ViewN/AView Earnings Details
8/29/2016Q1 2017C($0.01)ViewN/AView Earnings Details
7/29/2016Q4 2016C($0.02)ViewN/AView Earnings Details
2/29/2016Q3 2016C($0.01)ViewN/AView Earnings Details
11/26/2015Q2 2016C($0.02)ViewN/AView Earnings Details
8/21/2015Q1 2016C($0.01)ViewN/AView Earnings Details
7/28/2015Q4 2015C($0.02)ViewN/AView Earnings Details
2/27/2015Q3 2015C($0.02)ViewN/AView Earnings Details
11/28/2014Q2 2015C($0.04)C($0.03)ViewN/AView Earnings Details
8/27/2014Q1 2015C($0.04)ViewN/AView Earnings Details
7/28/2014Q4 2014C($0.03)ViewN/AView Earnings Details
2/27/2014Q3 2014C($0.03)ViewN/AView Earnings Details
11/28/2013Q2 2014C($0.02)ViewN/AView Earnings Details
8/28/2013Q1 2014C($0.02)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Antibe Therapeutics (CVE:ATE) Earnings Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q2 20181($0.01)($0.01)($0.01)
Q3 20181($0.01)($0.01)($0.01)
Q4 20181($0.01)($0.01)($0.01)
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Dividend History for Antibe Therapeutics (CVE:ATE)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Antibe Therapeutics (CVE ATE) Insider Trading and Institutional Ownership History

Insider Trades by Quarter for Antibe Therapeutics (CVE:ATE)

Antibe Therapeutics (CVE ATE) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/29/2016Scott Wilson CurtisInsiderBuy19,500C$0.13C$2,535.00
3/28/2016Scott Wilson CurtisInsiderBuy30,500C$0.13C$3,965.00
(Data available from 1/1/2013 forward)

Headlines

Antibe Therapeutics (CVE ATE) News Headlines

Source:
DateHeadline
Antibe Therapeutics Engages Brand Institute to Advise on Nonproprietary Name for ATB-346Antibe Therapeutics Engages Brand Institute to Advise on Nonproprietary Name for ATB-346
www.businesswire.com - January 18 at 6:56 PM
Antibe Therapeutics Engages Brand Institute to Advise on Nonproprietary Name for ATB-346 - Business Wire (press release)Antibe Therapeutics Engages Brand Institute to Advise on Nonproprietary Name for ATB-346 - Business Wire (press release)
www.businesswire.com - January 17 at 10:50 AM
Antibe Therapeutics Reports Q2 2018 Interim Financial and Operating Results and Provides Corporate UpdateAntibe Therapeutics Reports Q2 2018 Interim Financial and Operating Results and Provides Corporate Update
www.businesswire.com - November 29 at 10:59 AM
Antibe Therapeutics Announces Key US Distribution Partnership For Its Subsidiary, CitagenixAntibe Therapeutics Announces Key US Distribution Partnership For Its Subsidiary, Citagenix
www.thestreet.com - October 26 at 9:10 PM
Antibe Therapeutics Announces Key US Distribution Partnership for Its Subsidiary, Citagenix - Business Wire (press release)Antibe Therapeutics Announces Key US Distribution Partnership for Its Subsidiary, Citagenix - Business Wire (press release)
www.businesswire.com - October 26 at 10:12 AM
Antibe Therapeutics To Attend 2017 CPhI Worldwide Conference To Continue Partnering DiscussionsAntibe Therapeutics To Attend 2017 CPhI Worldwide Conference To Continue Partnering Discussions
www.thestreet.com - October 20 at 5:56 PM
Antibe Therapeutics Announces Enrollment of First Subjects in Phase 2B GI Safety Study for Lead Drug, ATB-346Antibe Therapeutics Announces Enrollment of First Subjects in Phase 2B GI Safety Study for Lead Drug, ATB-346
www.businesswire.com - September 8 at 4:33 PM
Antibe Therapeutics Reports Q1 2018 Interim Financial and Operating Results - Business Wire (press release)Antibe Therapeutics Reports Q1 2018 Interim Financial and Operating Results - Business Wire (press release)
www.businesswire.com - August 29 at 9:24 PM
Antibe Therapeutics Inc (ATE) to Release Earnings on MondayAntibe Therapeutics Inc (ATE) to Release Earnings on Monday
www.americanbankingnews.com - August 21 at 2:32 AM
Antibe Therapeutics Receives Approval to Initiate Phase 2 Gastrointestinal Endoscopy Clinical TrialAntibe Therapeutics Receives Approval to Initiate Phase 2 Gastrointestinal Endoscopy Clinical Trial
www.businesswire.com - August 2 at 4:56 PM
Antibe Therapeutics Reports 2017 Year-End Financial and Operating Results - Business Wire (press release)Antibe Therapeutics Reports 2017 Year-End Financial and Operating Results - Business Wire (press release)
www.businesswire.com - July 28 at 10:24 PM
Antibe Therapeutics Inc (CVE:ATE) Scheduled to Post Earnings on ThursdayAntibe Therapeutics Inc (CVE:ATE) Scheduled to Post Earnings on Thursday
www.americanbankingnews.com - July 22 at 11:27 AM
Antibe Therapeutics Inc. Announces Closing of Public OfferingAntibe Therapeutics Inc. Announces Closing of Public Offering
www.businesswire.com - June 22 at 3:43 PM
Antibe Therapeutics Inc. Announces Closing of Public Offering - Business Wire (press release)Antibe Therapeutics Inc. Announces Closing of Public Offering - Business Wire (press release)
www.businesswire.com - June 21 at 4:35 PM
Antibe Therapeutics Inc. Announces Filing of Final Short Form ProspectusAntibe Therapeutics Inc. Announces Filing of Final Short Form Prospectus
www.businesswire.com - June 17 at 3:46 PM
Antibe Therapeutics Inc. Announces Filing of Final Short Form Prospectus - Business Wire (press release)Antibe Therapeutics Inc. Announces Filing of Final Short Form Prospectus - Business Wire (press release)
www.businesswire.com - June 16 at 4:24 PM
Antibe Therapeutics Inc. Announces Pricing of Offering - Business Wire (press release)Antibe Therapeutics Inc. Announces Pricing of Offering - Business Wire (press release)
www.businesswire.com - May 26 at 3:57 PM
IIROC Trading Halt - ATEIIROC Trading Halt - ATE
www.bizjournals.com - May 25 at 1:05 AM
Antibe Therapeutics Advances Development of ATB-352 in Wake of Growing Global Opioid Epidemic - Business Wire (press release)Antibe Therapeutics Advances Development of ATB-352 in Wake of Growing Global Opioid Epidemic - Business Wire (press release)
www.businesswire.com - April 26 at 8:57 PM
Antibe Therapeutics Advances Development of ATB-352 in Wake of Growing Global Opioid EpidemicAntibe Therapeutics Advances Development of ATB-352 in Wake of Growing Global Opioid Epidemic
www.businesswire.com - April 26 at 3:56 PM
Antibe Therapeutics to Present at Bloom Burton & Co. Healthcare Investor Conference - Business Wire (press release)Antibe Therapeutics to Present at Bloom Burton & Co. Healthcare Investor Conference - Business Wire (press release)
www.businesswire.com - April 25 at 3:39 PM
Antibe Therapeutics to Present at Bloom Burton & Co. Healthcare Investor ConferenceAntibe Therapeutics to Present at Bloom Burton & Co. Healthcare Investor Conference
www.businesswire.com - April 24 at 3:42 PM
Antibe Therapeutics Provides Update on Clinical Development Program for Its Lead Drug, ATB-346 - Business Wire (press release)Antibe Therapeutics Provides Update on Clinical Development Program for Its Lead Drug, ATB-346 - Business Wire (press release)
www.businesswire.com - April 18 at 3:37 PM
Antibe Therapeutics Provides Update on Clinical Development Program for Its Lead Drug, ATB-346Antibe Therapeutics Provides Update on Clinical Development Program for Its Lead Drug, ATB-346
www.businesswire.com - April 18 at 9:58 AM
Antibes Founder and Chief Scientific Officer to Receive Distinguished Lifetime Achievement Award in Research - Business Wire (press release)Antibe's Founder and Chief Scientific Officer to Receive Distinguished Lifetime Achievement Award in Research - Business Wire (press release)
www.businesswire.com - March 28 at 3:39 PM
Antibe’s Founder and Chief Scientific Officer to Receive Distinguished Lifetime Achievement Award in ResearchAntibe’s Founder and Chief Scientific Officer to Receive Distinguished Lifetime Achievement Award in Research
www.businesswire.com - March 28 at 11:08 AM
Antibe Therapeutics Reports Q3 2017 Interim Financial and Operating ResultsAntibe Therapeutics Reports Q3 2017 Interim Financial and Operating Results
www.businesswire.com - March 1 at 8:41 PM
Antibe Therapeutics Enters into Regional Licensing DealAntibe Therapeutics Enters into Regional Licensing Deal
www.businesswire.com - February 24 at 6:12 PM
Antibe Therapeutics Engages MKR Group for US Investor Relations - Business Wire (press release)Antibe Therapeutics Engages MKR Group for US Investor Relations - Business Wire (press release)
www.businesswire.com - February 22 at 11:22 AM
Antibe Therapeutics Announces the Launch of PentOS OI™ Max, Its Newest Bone Graft Substitute for Oral and ... - Business Wire (press release)Antibe Therapeutics Announces the Launch of PentOS OI™ Max, Its Newest Bone Graft Substitute for Oral and ... - Business Wire (press release)
www.businesswire.com - January 31 at 8:53 PM
Antibe Therapeutics Announces Change of Auditor to Ernst & YoungAntibe Therapeutics Announces Change of Auditor to Ernst & Young
www.businesswire.com - January 19 at 2:19 AM
Antibe Therapeutics Completes Final Closing of Private Placement Bringing Total Proceeds to $2.7 MillionAntibe Therapeutics Completes Final Closing of Private Placement Bringing Total Proceeds to $2.7 Million
www.businesswire.com - December 22 at 2:44 AM
Antibe Therapeutics Completes Final Closing of Private Placement Bringing Total Proceeds to $2.7 Million - Business Wire (press release)Antibe Therapeutics Completes Final Closing of Private Placement Bringing Total Proceeds to $2.7 Million - Business Wire (press release)
www.businesswire.com - December 21 at 9:44 PM
Antibe Therapeutics Raises $2.4 Million in First Tranche of Private Placement - Business Wire (press release)Antibe Therapeutics Raises $2.4 Million in First Tranche of Private Placement - Business Wire (press release)
www.businesswire.com - December 17 at 1:59 AM
Antibe Therapeutics Raises $2.4 Million in First Tranche of Private PlacementAntibe Therapeutics Raises $2.4 Million in First Tranche of Private Placement
www.businesswire.com - December 16 at 3:56 PM
Antibe Therapeutics Reports Q2 2017 Interim Financial and Operating Results - Business Wire (press release)Antibe Therapeutics Reports Q2 2017 Interim Financial and Operating Results - Business Wire (press release)
www.businesswire.com - November 30 at 8:42 PM
Antibe Therapeutics Reports Q2 2017 Interim Financial and Operating ResultsAntibe Therapeutics Reports Q2 2017 Interim Financial and Operating Results
www.businesswire.com - November 30 at 9:21 AM
Research Reports Initiated on Healthcare Stocks OrganiGram Holdings, Aphria, Antibe Therapeutics, and biOasis TechnologiesResearch Reports Initiated on Healthcare Stocks OrganiGram Holdings, Aphria, Antibe Therapeutics, and biOasis Technologies
www.baystreet.ca - November 29 at 4:49 PM
Antibe Therapeutics Confirms Non-Addictive Properties for Its Second Pipeline Drug, ATB-352, a Potent, Non-Addictive Pain-KillerAntibe Therapeutics Confirms Non-Addictive Properties for Its Second Pipeline Drug, ATB-352, a Potent, Non-Addictive Pain-Killer
www.businesswire.com - October 17 at 8:27 AM
Antibe Therapeutics Announces Launch of Strategic Growth Initiative in the U.S. Market for Dental BiologicsAntibe Therapeutics Announces Launch of Strategic Growth Initiative in the U.S. Market for Dental Biologics
www.businesswire.com - October 11 at 3:41 PM
Antibe Therapeutics to Present at 2016 Rodman & Renshaw Global Investment ConferenceAntibe Therapeutics to Present at 2016 Rodman & Renshaw Global Investment Conference
www.businesswire.com - September 7 at 12:34 PM
Antibe Therapeutics Reports Q1 2017 Interim Financial and Operating ResultsAntibe Therapeutics Reports Q1 2017 Interim Financial and Operating Results
www.businesswire.com - August 30 at 3:37 PM
Antibe Therapeutics Announces Successful Phase 2 Trial of ATB-346 in OsteoarthritisAntibe Therapeutics Announces Successful Phase 2 Trial of ATB-346 in Osteoarthritis
www.businesswire.com - August 8 at 8:25 AM
Antibe Therapeutics Announces the Appointment of New Board Member and Provides Update on Phase 2 Trial of ATB-346Antibe Therapeutics Announces the Appointment of New Board Member and Provides Update on Phase 2 Trial of ATB-346
www.businesswire.com - July 19 at 9:49 AM
Antibe Therapeutics Raises $968,500 in First Tranche of Non-Brokered Private PlacementAntibe Therapeutics Raises $968,500 in First Tranche of Non-Brokered Private Placement
www.streetinsider.com - June 10 at 9:28 PM
Antibe Therapeutics Presenting Update on ATB-346 at International Hydrogen Sulfide ConferenceAntibe Therapeutics Presenting Update on ATB-346 at International Hydrogen Sulfide Conference
www.businesswire.com - May 30 at 10:50 AM
Antibe Therapeutics To Present At 2016 Bloom Burton & Co. Healthcare Investor ConferenceAntibe Therapeutics To Present At 2016 Bloom Burton & Co. Healthcare Investor Conference
www.thestreet.com - May 2 at 11:57 AM
Antibe Therapeutics Announces the Launch of PentOS OI™ Putty, a High-Quality Bone Graft Substitute for Oral and Maxillofacial SurgeryAntibe Therapeutics Announces the Launch of PentOS OI™ Putty, a High-Quality Bone Graft Substitute for Oral and Maxillofacial Surgery
www.businesswire.com - April 18 at 11:28 AM
Antibe Therapeutics Announces Grant Of Stock OptionsAntibe Therapeutics Announces Grant Of Stock Options
www.thestreet.com - March 10 at 10:03 AM
Antibe Therapeutics ATB-346 Receives Approval For Phase 2 Clinical Trial In Osteoarthritis PatientsAntibe Therapeutics' ATB-346 Receives Approval For Phase 2 Clinical Trial In Osteoarthritis Patients
www.thestreet.com - March 7 at 9:59 AM

SEC Filings

Antibe Therapeutics (CVE:ATE) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Financials are not available for this stock.

Chart

Antibe Therapeutics (CVE ATE) Stock Chart for Tuesday, January, 23, 2018

Loading chart…

This page was last updated on 1/23/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.